Janux's CEO David Campbell reviews this week's data from JANX007, the company's PSMA x CD3 masked bispecific for prostate cancer
He describes how the improvement over data from earlier this year gives him confidence in the strength of the signal he sees in this data, the next steps ahead, what the data suggests about the overall platform, and how Janux thinks about business development.